Calanolide A

Calanolide A

SCHEMBL140017

CCCc1cc(=O)oc2c3c(c4c(c12)OC(C)(C)C=C4)O[C@H](C)[C@@H](C)[C@@H]3O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 1.00
▸ CA12 O43570 2/20 1.00
▸ CA1 P00915 2/20 1.00
▸ CA2 P00918 2/20 1.00
▸ CA7 P43166 2/20 1.00
▸ CA9 Q16790 2/20 1.00
▸ APAF1 O14727 1/20 1.00
▸ MAPK1 P28482 1/20 1.00
▸ NPSR1 Q6W5P4 1/20 1.00
▸ CA13 Q8N1Q1 1/20 1.00
▸ PDE4D Q08499 2/20 0.40
▸ HIF1A Q16665 4/20 0.35
▸ EPAS1 Q99814 4/20 0.35
▸ HCAR2 Q8TDS4 3/20 0.33
▸ TSSK1B Q9BXA7 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ FFAR3 O14843 1/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
(+)-Calanolide B SCHEMBL212038 1.00 ALDH1A1 (1.00) ALDH1A1CA12CA1CA2CA7
Calanolide C SCHEMBL7036135 1.00 ALDH1A1 (1.00) ALDH1A1CA12CA1CA2CA7
Costatolide SCHEMBL30544160 1.00 ALDH1A1 (1.00) ALDH1A1CA12CA1CA2CA7
(-)-Calanolide A SCHEMBL29803798 1.00 ALDH1A1 (1.00) ALDH1A1CA12CA1CA2CA7
Calanolide A SCHEMBL30075237 1.00 ALDH1A1 (1.00) ALDH1A1CA12CA1CA2CA7
(-)-Calanolide A SCHEMBL8927754 1.00 ALDH1A1 (1.00) ALDH1A1CA12CA1CA2CA7
Costatolide SCHEMBL29397227 1.00 ALDH1A1 (1.00) ALDH1A1CA12CA1CA2CA7
Costatolide SCHEMBL29402951 1.00 ALDH1A1 (1.00) ALDH1A1CA12CA1CA2CA7
Costatolide SCHEMBL8927756 1.00 ALDH1A1 (1.00) ALDH1A1CA12CA1CA2CA7
SCHEMBL19596735 0.90 ALDH1A1 (0.82) ALDH1A1CA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 5514 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260108619-A1 CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2026-04-23 — — US claimed
US-12576124-B2 Formulation of a conjugate of a tubulysin analog to a cell-binding molecule HANGZHOU DAC BIOTECH CO., LTD (CN) 2026-03-17 — — US claimed
US-20250339551-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) 2025-11-06 — — US claimed
EP-4642484-A1 TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE Hangzhou Seehe Biotechnology Co., Ltd (CN) 2025-11-05 — — EP claimed
EP-4642492-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES Hangzhou Seehe Biotechnology Co., Ltd (CN) 2025-11-05 — — EP claimed
EP-4566670-A2 MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS Gilead Sciences, Inc. (US) 2025-06-11 — — EP claimed
US-12220464-B2 Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof HANGZHOU DAC BIOTECH CO., LTD. (CN) 2025-02-11 — — US claimed
WO-2024239281-A1 TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) 2024-11-28 — — WO claimed
WO-2024240173-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) 2024-11-28 — — WO claimed
EP-4426741-A1 BCMA MONOCLONAL ANTIBODY AND THE ANTIBODY-DRUG CONJUGATE Hangzhou DAC Biotech Co., Ltd. (CN) 2024-09-11 — — EP claimed
WO-1998038193-A1 METHOD FOR THE PREPARATION OF (+)-CALANOLIDE A AND ANALOGUES THEREOF MEDICHEM RESEARCH, INC. (US) 1998-09-03 — — WO claimed
EP-0775130-A1 METHOD FOR THE PREPARATION OF (+/-)-CALANOLIDE A AND INTERMEDIATES THEREOF MEDICHEM RESEARCH, INC. (US) 1997-05-28 — — EP claimed
US-5608085-A Synthesis of optically active calanolides A and B and enantiomers and related compounds THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) 1997-03-04 — — US claimed
US-5591770-A TREATING HUMAN T-CELL LYMPHOMA/LEUKEMIA INFECTIONS THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1997-01-07 — — US claimed
WO-1996026934-A1 SYNTHESIS OF OPTICALLY ACTIVE CALANOLIDES A AND B AND ENANTIOMERS AND RELATED COMPOUNDS THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) 1996-09-06 — — WO claimed
EP-0699202-A1 CALANOLIDE AND RELATED ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1996-03-06 — — EP claimed
WO-1996004263-A1 METHOD FOR THE PREPARATION OF (±)-CALANOLIDE A AND INTERMEDIATES THEREOF MEDICHEM RESEARCH, INC. (US) 1996-02-15 — — WO claimed
US-5489697-A Method for the preparation of (+)-calanolide A and intermediates thereof MEDICHEM RESEARCH, INC. (US) 1996-02-06 — — US claimed
EP-0633887-A1 CALANOLIDE ANTIVIRAL COMPOUNDS, COMPOSITIONS AND USES THEREOF THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1995-01-18 — — EP claimed
WO-1994028000-A1 CALANOLIDE AND RELATED ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1994-12-08 — — WO claimed
Send feedback